<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - TERBUTALINE SULFATE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>TERBUTALINE SULFATE</h1>

        <p><a href="../drugClass/PHP34629.html">SELECTIVE BETA2 AGONISTS</a></p>

      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Asthma</span>,
                <span class="indication">Other conditions associated with reversible airways obstruction</span>,
            </h4>
            <p class="specificity"><span class="route">By inhalation of nebulised solution</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 2.5 mg 3 times a day for 1&#8211;2 weeks, then increased to up to 5 mg 3 times a day, use by inhalation preferred over by mouth.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                250&#8211;500 micrograms up to 4 times a day, reserve intravenous beta2 agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                90&#8211;300 micrograms/hour for 8-10 hours, to be administered as a solution containing 3&#8211;5 micrograms/mL, high doses require close monitoring, reserve intravenous beta2 agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                500 micrograms up to 4 times a day, for persistent symptoms.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                5&#8211;10 mg 2&#8211;4 times a day, additional doses may be necessary in severe acute asthma.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Acute asthma</span>,
            </h4>
            <p class="specificity"><span class="route">By continuous intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose child"><strong>For children 2&#8211;14 years</strong><br/>
                10 micrograms/kg up to 4 times a day (max. per dose 300 micrograms), reserve intravenous beta2 agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect.</li>
              <li class="dose child"><strong>For children 15&#8211;17 years</strong><br/>
                250&#8211;500 micrograms up to 4 times a day, reserve intravenous beta2 agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect.</li>
              <li class="dose child"><strong>For children </strong><br/>
                Loading dose 2&#8211;4 micrograms/kg, then 1&#8211;10 micrograms/kg/hour, dose to be adjusted according to response and heart rate, close monitoring is required for doses above 10 micrograms/kg/hour, reserve intravenous beta2 agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Moderate, severe, or life-threatening acute asthma</span>,
            </h4>
            <p class="specificity"><span class="route">By inhalation of nebulised solution</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 10 mg, then 10 mg every 20&#8211;30 minutes or when required, give via oxygen-driven nebuliser if available.</li>
              <li class="dose child"><strong>For children 1 month&#8211;4 years</strong><br/>
                Initially 5 mg, then 5 mg every 20&#8211;30 minutes or when required, give via oxygen-driven nebuliser if available.</li>
              <li class="dose child"><strong>For children 5&#8211;11 years</strong><br/>
                Initially 5&#8211;10 mg, then 5&#8211;10 mg every 20&#8211;30 minutes or when required, give via oxygen-driven nebuliser if available.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Initially 10 mg, then 10 mg every 20&#8211;30 minutes or when required, give via oxygen-driven nebuliser if available.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Exacerbation of reversible airways obstruction (including nocturnal asthma)</span>,
                <span class="indication">Prevention of exercise-induced bronchospasm</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose child"><strong>For children 5&#8211;17 years</strong><br/>
                500 micrograms up to 4 times a day, for occasional use only.</li>
              <li class="dose child"><strong>For children 1 month&#8211;6 years</strong><br/>
                75 micrograms/kg 3 times a day (max. per dose 2.5 mg).</li>
              <li class="dose child"><strong>For children 7&#8211;14 years</strong><br/>
                2.5 mg 2&#8211;3 times a day.</li>
              <li class="dose child"><strong>For children 15&#8211;17 years</strong><br/>
                Initially 2.5 mg 3 times a day, then increased if necessary to 5 mg 3 times a day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Uncomplicated premature labour (between 22 and 37 weeks of gestation) (specialist supervision in hospital)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 5 micrograms/minute for 20 minutes, then increased in steps of 2.5 micrograms/minute every 20 minutes until contractions have ceased (more than 10 micrograms/minute should seldom be given&#8212;20 micrograms/minute should not be exceeded), continue for 1 hour, then reduced in steps of 2.5 micrograms/minute every 20 minutes to lowest dose that maintains suppression (maximum total duration 48 hours).</li>
            </ul>
          </section>
        </section>
        
        
        
        
            <section class="pharmacokinetics">
              <h3>Pharmacokinetics</h3>
              <p>At recommended inhaled doses, the duration of action of terbutaline is about 3 to 5 hours.</p>
            </section>
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Inhaled drugs for asthma can be taken as normal during pregnancy.</p>
            </section>
      </section>



      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>notKnown:</strong> Nausea,
              </p>
        
          <h3>Specific side effects</h3>
              <p>
                <strong>notKnown:</strong> muscle tension in adults, pulmonary oedema in adults, vomiting in adults,
              </p>
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>For <i>continuous intravenous infusion</i>, dilute to a concentration of 5&#8239;micrograms/mL with Glucose 5% <i>or</i> Sodium Chloride 0.9%; if fluid-restricted, dilute to a concentration of 100&#8239;micrograms/mL.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">When used by <ph outputclass="route">inhalation</ph></h3>
              <p>For <i>nebulisation</i>, dilute nebuliser solution with sterile Sodium Chloride 0.9% solution according to nebuliser type and duration of administration; terbutaline and ipratropium bromide solutions are compatible and may be mixed for nebulisation.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in adults</h3>
              <p>For <i>bronchodilation</i> by <i>continuous intravenous infusion</i>, dilute 1.5&#8211;2.5&#8239;mg with 500&#8239;mL glucose 5% or sodium chloride 0.9% and give over 8&#8211;10 hours.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in adults</h3>
              <p>For <i>premature labour</i> by <i>continuous intravenous infusion</i>, dilute in glucose 5% and give <i>via</i> controlled infusion device preferably a syringe pump; if syringe pump available dilute to a concentration of 100&#8239;micrograms/mL; if syringe pump not available dilute to a concentration of 10&#8239;micrograms/mL; close attention to patient's fluid and electrolyte status essential.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <h3 class="specificity">When used by <ph outputclass="route">inhalation</ph></h3>
              <p>
            <i>For inhalation by dry powder</i>, advise patients and carers not to exceed prescribed dose and to follow manufacturer&#8217;s directions; if a previously effective dose of inhaled terbutaline fails to provide at least 3 hours relief, a doctor&#8217;s advice should be obtained as soon as possible.</p>
            </section>
            <section class="generalPatientAdvice">
              <h3 class="specificity">When used by <ph outputclass="route">inhalation</ph></h3>
              <p>
            <i>For inhalation by nebuliser</i>, the dose given by nebuliser is substantially higher than that given by inhaler. Patients should therefore be warned that it is dangerous to exceed the prescribed dose and they should seek medical advice if they fail to respond to the usual dose of the respirator solution.</p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
              <strong>:</strong>
            Mild to moderate pre-eclampsia (when used for uncomplicated premature labour) in adults
          </li>
          <li>
              <strong>:</strong>
            suspected cardiovascular disease (should be assessed by a cardiologist before initiating therapy for uncomplicated premature labour) in adults
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <h3 class="specificity">In adults</h3>
              <p>In uncomplicated premature labour it is important to monitor blood pressure, pulse rate (should not exceed 120 beats per minute), ECG (discontinue treatment if signs of myocardial ischaemia develop), blood glucose and lactate concentrations, and the patient&#8217;s fluid and electrolyte status (avoid over-hydration&#8212;discontinue drug immediately and initiate diuretic therapy if pulmonary oedema occurs).</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in children</h3>
              <p>Tablets not licensed for use in children under 7 years.</p>
            </section>
            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use or <ph outputclass="route">subcutaneous</ph> use in children</h3>
              <p>Injection not licensed for use in children under 2 years.</p>
            </section>
      </section>










      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of TERBUTALINE SULFATE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            solution for injection,

            <div id="PHP76370"><a href="../medicinalForm/PHP76370.html" data-target="#PHP76370" data-action="load">Tablet</a></div>
            <div id="PHP76351"><a href="../medicinalForm/PHP76351.html" data-target="#PHP76351" data-action="load">Oral solution</a></div>
            <div id="PHP76357"><a href="../medicinalForm/PHP76357.html" data-target="#PHP76357" data-action="load">Solution for injection</a></div>
            <div id="PHP76376"><a href="../medicinalForm/PHP76376.html" data-target="#PHP76376" data-action="load">Inhalation powder</a></div>
            <div id="PHP76390"><a href="../medicinalForm/PHP76390.html" data-target="#PHP76390" data-action="load">Nebuliser liquid</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
